Biodegradable stents after lung transplantation

Fuehner, Thomas; Suhling, Hendrik; Greer, Mark; Wiesner, Olaf; Dierich, Martin; Warnecke, G.; Haverich, Axel; Welte, Tobias; Gottlieb, Jens

doi:10.1111/tri.12095

Cited by 28 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lesions persisting after four treatments are classified as refractory and considered for stenting. Use of SEMS has been entirely superseded by polydioxanone stents, with our experiences of both having been published previously . Suitable lesions failing second‐line treatment are now routinely offered PCB treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Well‐documented complications including stent fracture, erosion of adjacent structures, mucus retention, microbiological colonization and in‐stent re‐stenosis, however, resulted in a Food and Drug Administration advisory, cautioning on their use in nonmalignant disease . Alternatives including silicone and polydioxanone biodegradable stents negate many of these issues and have replaced SEMS in some centers, but long‐term outcomes remain disappointing .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Paclitaxel-Coated Balloons in Refractory Nonanastomostic Airway Stenosis Following Lung Transplantation

Greer

Fuehner

Warnecke

et al. 2014

American Journal of Transplantation

View full text Add to dashboard Cite

Airway stenosis represents the commonest airway complication following lung transplantation, affecting between 7% and 18% of patients. Existing treatment options offer limited efficacy and can cause additional patient morbidity. Paclitaxel‐coated balloons (PCB) have proved effective in managing postinterventional coronary artery re‐stenosis. In a first‐in‐man study, we evaluated similar PCBs in refractory nonanastomotic airway stenosis in 12 patients. Following a single application, luminal patency was maintained in 50% at 270 days. No significant peri‐interventional or early postinterventional complications occurred. Given these encouraging initial findings, further studies appear warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Paclitaxel-Coated Balloons in Refractory Nonanastomostic Airway Stenosis Following Lung Transplantation

Greer

Fuehner

Warnecke

et al. 2014

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…Lischke et al reported their first clinical application in 6 post-LT patients where 5 of them were in good clinical condition after 4 years' follow-up (Lischke et al, 2011). Later, Fechner et al reported a larger case series with a total of 11 stents (Fuehner et al, 2013).…”

Section: Stent/splintmentioning

confidence: 99%

3D-bioprinted tracheal reconstruction: an overview

Frejo

Grande

2019

Bioelectron Med

View full text Add to dashboard Cite

Congenital tracheomalacia and tracheal stenosis are commonly seen in premature infants. In adulthood, are typically related with chronic obstructive pulmonary disease, and can occur secondarily from tracheostomy, prolong intubation, trauma, infection and tumors. Both conditions are life-threatening when not managed properly. There are still some surgical limitations for certain pathologies, however tissue engineering is a promising approach to treat massive airway dysfunctions. 3D-bioprinting have contributed to current preclinical and clinical efforts in airway reconstruction. Several strategies have been used to overcome the difficulty of airway reconstruction such as scaffold materials, construct designs, cellular types, biologic components, hydrogels and animal models used in tracheal reconstruction. Nevertheless, additional long-term in vivo studies need to be performed to assess the efficacy and safety of tissue-engineered tracheal grafts in terms of mechanical properties, behavior and, the possibility of further stenosis development.

show abstract

“…All other cases remained clinically well throughout the follow-up period. The research group of Fuehner recently reported a larger case series with biodegradable stents in post-LT patients (25). They inserted a total of 11 stents.…”

Section: Biodegradable Stentsmentioning

confidence: 99%

“…They concluded that SEMS can be used in selected post-LT patients since their removal could be safely and effectively accomplished if needed (30). A recent area of interest is the use of biodegradable stents in these patients with reasonable initial results (24,25). However, additional data is needed before they can be adopted in the armamentarium of thoracic surgeons and interventional pulmonologists.…”

Section: Commentarymentioning

confidence: 99%